Summary & Overview
HCPCS J1322: Elosulfase Alfa Injection, 1 mg
HCPCS Level II code J1322 designates a 1 mg unit of elosulfase alfa, an enzyme replacement therapy administered by injection or infusion. This code matters nationally because specialty biologic therapies carry high per-dose costs, have specific billing and coding requirements, and influence payer coverage policies and utilization management for rare metabolic disorders. The analysis covers major national payers and Medicare.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for elosulfase alfa, typical sites of service where the drug is delivered, and what the code captures on the claim line. The publication outlines benchmarks and reimbursement considerations that affect billing for high-cost injectable biologics, common modifier usage patterns where available, and the operational implications for provider billing workflows.
This summary provides actionable reference material for revenue cycle, coding compliance, and payer engagement teams seeking a national perspective on billing and reporting for J1322. Data not available in the input is noted where applicable rather than inferred.
Billing Code Overview
HCPCS Level II code J1322 represents an injectable therapy: elosulfase alfa, 1 mg. The service type is therapeutic infusion/injection, typically administered as an intravenous infusion or injection in an outpatient clinic, hospital outpatient department, or specialized infusion center. This code describes the drug unit of measure (per 1 mg) for elosulfase alfa used in enzyme replacement therapy. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with confirmed mucopolysaccharidosis type IVA (Morquio A syndrome) presents for scheduled intravenous enzyme replacement therapy with elosulfase alfa (J1322). The patient arrives at an outpatient infusion center or hospital outpatient infusion clinic for a recurring infusion administered by an infusion nurse under physician oversight. Typical workflow: pre-infusion nursing assessment (vitals, weight, review of recent labs), verify identity and therapy orders, check for allergies and previous infusion reactions, prepare and document the 1 mg elosulfase alfa dose (per vial billing unit J1322), obtain any required pre-medications (e.g., antihistamines, acetaminophen) if history indicates, establish IV access, administer infusion per manufacturer rate guidelines with monitoring for infusion-related reactions, document start and stop times and any adverse events, and discharge with return follow-up schedule. Typical site of service: outpatient infusion center, hospital outpatient department, or specialized pediatric infusion clinic. Typical patient scenario: recurrent, scheduled enzyme replacement therapy for a genetically confirmed lysosomal storage disorder, requiring periodic monitoring, potential pre-medication, and IV administration by trained infusion staff.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|